About Carolyne Zimmermann
Carolyne Zimmermann has been chief business officer of SonoThera since June 2023. She was previously chief business officer of 4D Molecular Therapeutics, and before that she led business development for Novartis's global cardiovascular and metabolic franchise.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Carolyne Zimmermann in the role, so the role may have started earlier or lasted longer.
SonoThera, Inc. Current
Chief Business Officer
2023 – Present · South San Francisco, CA
SonoThera develops nonviral genetic medicines that use ultrasound and imaging microbubbles to deliver DNA and RNA into chosen organs, starting with Duchenne muscular dystrophy.
4T
4D Molecular Therapeutics
Chief Business Officer
JF
Johnson & Johnson Innovation Center, San Francisco
Vice President of Transactions & Innovation Partnering
NO
Novartis
Head of Business Development, Global Cardiovascular and Metabolic Franchise
DC
dRx Capital
General Partner and founding member
Education
- BS, Engineering Sciences, University of California, San Diego
- MBA, Columbia Business School
Key Colleagues at Startups
The people Carolyne Zimmermann works with at each company, as listed on that company's latest Form D.
SonoThera, Inc. · Form D, Jun 30, 2026
SF
Steven Feinstein
Co-founder & Chief Scientific Officer
KG
Kenneth Greenberg
Co-founder, President & CEO, director
MD
Michael Davidson
Co-founder & Executive Chairman
RJ
Rajul Jain
Director
SG
Steven Gillis
Director
Rakhshita Dhar
Director
BH
Brian Halak
Director